Clinical trials: Single Dose
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose and pharmacokinetics of MLN0128 in patients with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia
- Trial name
- NCT01118689
- Testing
- MLN0128
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cachexia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses
This study is the first administration of GSK2881078 to humans. The intention of this study is to provide sufficient confidence in the safety of the molecule to inform progression to further repeat dose and proof of concept…
- Trial name
- NCT02045940
- Testing
- GSK2881078
- Where
- 2 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see: how the body processes the study medicine and if food affects the amount of study…
- Trial name
- NCT06686797
- Testing
- PF-08049820
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy
The purpose of this study is to evaluate the efficacy of the Asthma improvement of Flutiform K-haler after 12 weeks of treatment in patients with moderate to severe uncontrolled* asthma following mid-dose ICS/LABA DPI therapy.
- Trial name
- SWIFT (NCT04124510)
- Testing
- Brand Name: Flutiform K-haler
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Mundipharma Korea Ltd
Advanced Solid Tumors
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
This is a non-randomised study in patients with advanced solid malignancies
- Trial name
- ADME (NCT05008913)
- Testing
- [14C]Adavosertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Psoriasis
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
The purpose of this study is to evaluate the potential effects of a single dose of 200 milligram (mg) guselkumab on the plasma concentrations of a cocktail of representative probe substrates of Cytochrome P450 isozymes (CYP3A4…
- Trial name
- NCT02397382
- Testing
- Guselkumab, Midazolam, Warfarin
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with triple negative breast cancer who have failed in routine systemic treatment.
- Trial name
- NCT02838823
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Cystic Fibrosis
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
- Trial name
- NCT06237335
- Testing
- RCT2100, Ivacaftor
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ReCode Therapeutics
Osteoarthritis, Knee
Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty
This study evaluates single dose of Denosumab in decreasing systemic and periprosthetic bone resorption after Total Knee Arthroplasty compared to placebo in 60 patients (30 placebo and 30 Denosumab) within 2 months after surgery.
- Trial name
- NCT05559268
- Testing
- Denosumab 60 MG/ML Injectable Solution [Prolia]
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Idiopathic Pulmonary Fibrosis
Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
GSK3008348 is being developed as a treatment for IPF. A first-time-in-human study showed that single nebulized doses of 1-3000 micrograms (mcg) GSK3008348 in healthy volunteers were well tolerated, with pharmacokinetic (PK)…
- Trial name
- NCT03069989
- Testing
- GSK3008348, [18F]-FBA-A20FMDV2
- Where
- 3 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Healthy
Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults
The purpose of this study is to describe the pharmacokinetics of a new oral liquid moxifloxacin formulation and the influence of concommitant food intake on the pharmacokinetics in healthy adults compared to the marketed oral…
- Trial name
- NCT01073891
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Moxifloxacin (BAY12-8039)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Ischemic Heart Disease
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.
- Trial name
- NCT01847391
- Testing
- GS-6615
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Healthy Volunteers
FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability of single and multiple intravenous ascending doses of ANT3310, a novel, specific, competitive inhibitor of serine β-lactamases, alone and in combination with…
- Trial name
- NCT05905913
- Testing
- ANT3310, Meropenem
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Antabio
Hypertension
Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers
This is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.
- Trial name
- NCT03662620
- Testing
- Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
- Where
- South Korea
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Asthma
Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation
This is an open-label, five- period, cross-over, randomized, single dose, single centre study in healthy subjects. This is the second clinical study for the UD-DPI.
- Trial name
- NCT02218723
- Testing
- FF UD-DPI, FF ELLIPTA DPI
- Where
- 2 sites in Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body
The primary objective of this trial is to investigate the relative bioavailability of BI 655130 administered as two subcutaneous injections in the left and right periumbilical region compared to a single subcutaneous…
- Trial name
- NCT03617835
- Testing
- R - Low dose of BI 655130, T1 - Low dose of BI 655130, T2 - Low dose of BI 655130
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00880490
- Testing
- Inhaled PT005, Formoterol Fumarate 12 mcg (Foradil Aerolizer)
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 34 people
- Sponsor
- Pearl Therapeutics, Inc.
Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC)
YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer
This phase I study tests a personalized cancer vaccine (Neo-DC) for men with advanced prostate cancer (metastatic castration-resistant prostate cancer, or mCRPC) that has continued to grow despite standard hormone therapies and…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC), Prostate Neoplasms
- Trial name
- YS247 (NCT07583160)
- Testing
- Autologous Neoantigen-Pulsed Dendritic Cell Vaccine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
Safety Issues, Tolerance
Study to Evaluate LPH-5 in Healthy Subjects
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.
- Trial name
- NCT06722820
- Testing
- LPH-5
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Lophora
Healthy Japanese Volunteers
A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects
The purpose of the study is to evaluate the safety and tolerability and serum Pharmacokinetics (PK) of single doses of UCB0107 administered in healthy Japanese subjects.
- Trial name
- NCT03605082
- Testing
- UCB0107
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.